[14C]SSS17

[14C]SSS17 is a carbon-14 radiolabeled version of **SSS17**, an investigational small molecule **hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI)** developed by **3SBio** (Shenyang Sunshine Pharmaceutical). SSS17 is being developed for the treatment of **anemia associated with chronic kidney disease (CKD)**. Its mechanism of action involves inhibiting the prolyl hydroxylase enzymes that normally facilitate the degradation of HIF-α; by stabilizing HIF-α, the drug promotes the transcription of erythropoietin (EPO) and other genes involved in red blood cell production and iron metabolism. The radiolabeled `[14C]SSS17` variant is specifically utilized in Phase 1 mass balance studies to characterize the absorption, distribution, metabolism, and excretion (ADME) profile of the compound in humans, providing essential pharmacokinetic data for clinical development.